GlaxoSmithKline is paying $176m for a 10% stake in University of Tübingen's RNA drug developer in connection with a strategic partnership agreement.

CureVac, a Germany-based RNA therapy spinout of Eberhard Karls University of Tübingen, signed a strategic partnership agreement with pharmaceutical firm GlaxoSmithKline (GSK) today that will include a €150m ($176m) equity investment. GSK will also make a $141m upfront cash payment to CureVac and a reimbursable one-time payment of $35m to secure manufacturing capacity upon certification…

The rest of this content is only accessible to University Venturing: News, Data, and Events - Global University Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.